Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis

医学 嵌合抗原受体 细胞因子释放综合征 内科学 荟萃分析 科克伦图书馆 肿瘤科 CD19 免疫疗法 子群分析 淋巴瘤 神经毒性 抗原 胃肠病学 免疫学 毒性 癌症
作者
Zhitao Ying,Yuqin Song,Jun Zhu
出处
期刊:Frontiers in Pharmacology [Frontiers Media]
卷期号:13
标识
DOI:10.3389/fphar.2022.834113
摘要

Aim: To investigate the effectiveness and safety of using chimeric antigen receptor (CAR) T cell therapies targeting CD19 in patients with diffuse large B-cell lymphoma (DLBCL). Methods: PubMed, Embase, and the Cochrane Library were searched for reports published from database inception up to July 2021. The present meta-analysis included clinical response outcomes, survival outcomes, and safety analyses. For qualitative analysis that could not be combined, the data were presented in a tabular form. Subgroup analyses were also performed according to the costimulatory domains, generic names, and study designs. Results: Twenty-seven studies (1,687 patients) were included. The pooled 12-months overall survival (OS) rate was 63% (95%CI: 56-70%). The pooled best overall response (BOR) was 74.0% (95%CI: 67-79%), with a best complete response (BCR) of 48% (95%CI: 42-54%) and a 3-months CR rate (CRR) of 41% (95%CI: 35-47%). The subgroup analyses by costimulatory domain suggested statistically significant differences in BOR and BCR, whereas not in the 12-months OS rate and 3-months CRR. Among the patients evaluable for safety, 78% (95%CI: 68-87%), 6% (95%CI: 3-10%), 41% (95%CI: 31-52%), and 16% (95%CI: 10-24%) experienced cytokine release syndrome (CRS), severe CRS, neurotoxicity, and severe neurotoxicity, respectively. Compared with the CD28 costimulatory domain, the 4-1BB-based products showed a better safety profile on any-grade CRS (p < 0.01), severe CRS (p = 0.04), any-grade neurotoxicity (p < 0.01), and severe neurotoxicity (p < 0.01). Conclusion: Anti-CD19 CAR-T cell immunotherapy has promising effectiveness and tolerable severe AE profile in DLBCL patients. 4-1BB-based CAR-T cells have a similar 12-months OS rate and 3-months CRR with CD28-based products but a better safety profile. The costimulatory domain might not affect the survival outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Cpp完成签到 ,获得积分10
1秒前
贤惠的老黑完成签到 ,获得积分10
3秒前
ame1120发布了新的文献求助10
3秒前
倦梦还完成签到,获得积分10
5秒前
Sunrise完成签到,获得积分10
6秒前
yyyy发布了新的文献求助10
15秒前
自觉柠檬完成签到 ,获得积分10
19秒前
ergatoid完成签到,获得积分10
19秒前
Hao完成签到,获得积分10
20秒前
月亮煮粥完成签到,获得积分10
20秒前
欣欣完成签到 ,获得积分10
22秒前
现代的紫霜完成签到,获得积分10
23秒前
研学弟完成签到,获得积分10
24秒前
25秒前
jzmulyl完成签到,获得积分10
26秒前
cxdhxu完成签到 ,获得积分10
26秒前
852应助大橙子采纳,获得10
28秒前
务实雁梅完成签到,获得积分10
33秒前
酷波er应助廿伊采纳,获得30
34秒前
36秒前
张宝完成签到,获得积分10
38秒前
薄雪草完成签到,获得积分10
41秒前
大橙子发布了新的文献求助10
41秒前
快乐学习每一天完成签到 ,获得积分10
41秒前
薄荷味完成签到 ,获得积分0
43秒前
科研通AI2S应助笑林采纳,获得10
43秒前
无心的雅旋完成签到,获得积分10
44秒前
量子星尘发布了新的文献求助10
45秒前
Horizon完成签到 ,获得积分10
49秒前
Oliver完成签到 ,获得积分10
51秒前
Superman完成签到 ,获得积分10
54秒前
Tina酱完成签到 ,获得积分10
54秒前
琪琪完成签到,获得积分10
54秒前
双碳小王子完成签到,获得积分10
56秒前
smottom应助科研通管家采纳,获得10
58秒前
58秒前
明时完成签到,获得积分10
59秒前
杨瑞东完成签到 ,获得积分10
1分钟前
yyyy完成签到,获得积分10
1分钟前
缥缈的平卉完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022